Abstracts tagged "Adverse events"

Abstract Number: 1853 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients’ Experiences of Medication Side Effects and Subsequent Decision Making about Medications
Yomei Shaw¹, Ilinca D. Metes², Susan L. Zickmund³, Dawn McBride², Kelly A. Reckley², Stephen R. Wisniewski⁴, Larry W. Moreland², Mark S. Roberts¹ and Marc C. Levesque², ¹Department of Health Policy and Management, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, ²Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Epidemiology, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA
Background/Purpose: Medication adherence in rheumatoid arthritis (RA) patients can be influenced by their previous experiences with medication side effects. Negative experiences may lead patients to…
Abstract Number: 1854 • 2012 ACR/ARHP Annual Meeting
The Safety of Anti-TNF Biologic Agents in Rheumatoid Arthritis – A Meta-Analysis of 35 RCTs
Tzuyu Lin¹, Tatyana Shamliyan¹, Hyon Choi², Young Hee Rho³ and Karen Kuntz¹, ¹Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, MN, ²Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: The objectives of this systematic review were to study and update the safety of anti-TNF agents. We examined whether etanercept (ETN), compared to the…
Abstract Number: 1298 • 2012 ACR/ARHP Annual Meeting
Improvement of Treatment Outcome of Rheumatoid Arthritis with Salazosulfapyridine by Pharmacogenetic Approach
Shunichi Kumagai¹, Yoshiaki Hagiwara², Yoshihide Ichise¹, Sho Sendo³, Nobuhiko Okada¹, Jun Saegusa⁴ and Goh Tsuji⁵, ¹Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ²Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁴Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁵Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan
Background/Purpose: Salazosulfapyridine (SASP) is acetylated in liver by N-acetyltransferase2 (NAT2) in the track of metabolism. Previous studies have shown that genotyping of NAT2 is adequate…
Abstract Number: 1242 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Mike Nurmohamed¹, Yanjun Bao², James Signorovitch³, Parvez M. Mulani⁴ and Daniel Furst⁵, ¹VU University Medical Center & Jan van Breemen Research Institute, Amsterdam, Netherlands, ²AbbVie, North Chicago, IL, ³Analysis Group, Inc., Boston, MA, ⁴Abbott Laboratories, Abbott Park, IL, ⁵Div of Rheumatology, UCLA Medical School, Los Angeles, CA
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the…
Abstract Number: 1174 • 2012 ACR/ARHP Annual Meeting
Severe Adverse Events Associated with Use of Biologic Therapy in Juvenile Idiopathic Arthritis: A Single-Center Study
Ricardo A. G. Russo¹ and Marìa M. Katsicas², ¹Immunology & Rheumatology, Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ²Immunology & Rheumatology., Hospital de Pediatrìa Garrahan, Buenos Aires, Argentina
Background/Purpose: biologic agents have revolutionized the treatment of Juvenile Idiopathic Arthritis (JIA) and other conditions due to their high efficacy and safety. However, with the…
Abstract Number: 1150 • 2012 ACR/ARHP Annual Meeting
Adverse Events in Juvenile Idiopathic Arthritis: Results From the Enhanced Drug Safety Surveillance (EDSS) Pilot Project
Sarah Ringold¹, Audrey F. Hendrickson², Carol A. Wallace³ and Rachel E. Sobel⁴, ¹Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ²Rheumatology, Seattle Children's Research Institute, Seattle, WA, ³Pediatrics, Seattle Childrens Hospital, Seattle, WA, ⁴Epidemiology, Worldwide Safety Strategy, Pfizer, Inc., New York, NY
Background/Purpose: There are few data available regarding the rates of serious and important medical events (SAEs and IMEs) for most of the medications used to…
Abstract Number: 260 • 2012 ACR/ARHP Annual Meeting
Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program
Marc C. Hochberg¹, Steven B. Abramson², David S. Hungerford³, Edward McCarthy⁴, Eric P. Vignon⁵, Michael D. Smith⁶, Leslie Tive⁷, Kenneth M. Verburg⁶ and Christine R. West⁸, ¹Department of Medicine, University of Maryland, Baltimore, MD, ²Dept of Rheumatology/Medicine, NYU Langone Medical Center, New York, NY, ³Department of Ortho Surgery, Johns Hopkins University, Baltimore, MD, ⁴Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology 2B, Centre Hospitalier, Pierre Benite, France, ⁶Pfizer, Inc., Groton, CT, ⁷Arthritis, Pfizer Inc, New York, NY, ⁸Clinical Sciences, Pfizer, Williamston, MI
Background/Purpose: Tanezumab (TNZ) has been shown to be efficacious for pain and function in patients with hip and knee osteoarthritis (OA). Unexpected reports of adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].